Dr. Tripathy Discusses the MONALEESA-7 Trial in HR+ Breast Cancer
June 2nd 2019Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the MONALEESA-7 trial in hormone receptor-positive breast cancer.
Read More
Dr. Tripathy on Combination Strategies With CDK4/6 Inhibitors in Breast Cancer
March 9th 2019Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses combination strategies being investigated with CDK4/6 inhibitors in breast cancer.
Read More
CDK4/6 Inhibitors Play a Growing Role in Enhancing Endocrine Therapy
March 9th 2019For more than 100 years, endocrine therapy has been used for the treatment of breast cancer; since that time, we have learned much about the role of estrogen in the biology of normal breast cancer development.
Read More
Dr. Tripathy Discusses Impact of T-DM1 in HER2+ Breast Cancer
January 7th 2019Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the impact of T-DM1 in HER2-positive breast cancer.
Read More
Dr. Tripathy Discusses Pertuzumab in HER2+ Breast Cancer
December 21st 2018Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of pertuzumab in HER2-positive breast cancer.
Read More
Dr. Tripathy on Combination Strategies With CDK4/6 Inhibitors in HR+ Breast Cancer
September 10th 2018Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses combination strategies with CDK4/6 inhibitors for the treatment of patients with hormone receptor (HR)-positive breast cancer.
Read More
Dr. Tripathy on Frontline Endocrine Therapies in HR+ Breast Cancer
August 23rd 2018Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses frontline endocrine therapies for patients with hormone receptor (HR)-positive breast cancer.
Read More
Dr. Tripathy on the Management of HR+ Early-Stage Breast Cancer
July 13th 2018Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the management of hormone-receptor (HR)-positive early-stage breast cancer.
Read More
Dr. Tripathy on Impact of Olaparib Approval in BRCA-Positive Breast Cancer
March 8th 2018Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the FDA approval of olaparib (Lynparza) for patients with BRCA-positive breast cancers and the impact it has had on clinical practice. Tripathy shared this insight in an interview during the 35th Annual Miami Breast Cancer Conference.
Read More
Dr. Tripathy Discusses Neratinib in HER2+ Breast Cancer
December 12th 2017Debu Tripathy, MD, professor of medicine, chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses neratinib (Nerlynx) for the treatment of patients with HER2-positive breast cancer.
Read More
Dr. Tripathy on Standard and Emerging Treatment Advances for HER2+ Breast Cancer
March 22nd 2017Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses standard and emerging advances in the treatment of patients with HER2-positive breast cancer.
Read More
Dr. Tripathy on Immunotherapy Potential in HER2-Positive Breast Cancer
November 19th 2016Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the potential role of immunotherapy in the treatment of patients with HER2-positive breast cancer.
Read More
Dr. Tripathy on Neoadjuvant Agents for HER2+ Breast Cancer
November 16th 2016Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses agents that are available and in development in the neoadjuvant setting as treatments for patients with HER2-positive breast cancer.
Read More